Parameter | No. | Rsf-1 expression | p Value | |
Low exp. | High exp. | |||
Gender | ||||
Male | 108 | 54 | 54 | 0.428 |
Female | 64 | 36 | 28 | |
Age | ||||
<70 | 106 | 52 | 54 | 0.277 |
≧70 | 66 | 38 | 28 | |
Pre-treatment tumour status (Pre-T) | ||||
T1–T2 | 81 | 50 | 31 | 0.020* |
T3–T4 | 91 | 40 | 51 | |
Pre-treatment nodal status (Pre-N) | ||||
N0 | 125 | 64 | 61 | 0.630 |
N (+) | 47 | 26 | 21 | |
Post-treatment tumour status (Post-T) | ||||
T1–T2 | 86 | 59 | 27 | <0.001* |
T3–T4 | 86 | 31 | 55 | |
Post-treatment nodal status (Post-N) | ||||
N0 | 123 | 67 | 56 | 0.372 |
N1–N2 | 49 | 23 | 26 | |
Vascular invasion | ||||
Absent | 157 | 84 | 73 | 0.317 |
Present | 15 | 6 | 9 | |
Perineurial invasion | ||||
Absent | 167 | 88 | 79 | 0.575 |
Present | 5 | 2 | 3 | |
Tumour regression grade | ||||
Grade 0–1 | 37 | 14 | 23 | 0.028* |
Grade 2–3 | 118 | 63 | 55 | |
Grade 4 | 17 | 13 | 4 |
↵* Statistically significant.